Cellmid Ltd
ASX:CDY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cellmid Ltd
Income from Continuing Operations
Cellmid Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cellmid Ltd
ASX:CDY
|
Income from Continuing Operations
-AU$3.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Holista CollTech Ltd
ASX:HCT
|
Income from Continuing Operations
-AU$951.4k
|
CAGR 3-Years
14%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Bioxyne Ltd
ASX:BXN
|
Income from Continuing Operations
AU$8.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
37%
|
|
|
McPherson's Ltd
ASX:MCP
|
Income from Continuing Operations
-AU$17.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Star Combo Pharma Ltd
ASX:S66
|
Income from Continuing Operations
AU$5.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
B
|
Biome Australia Ltd
ASX:BIO
|
Income from Continuing Operations
AU$214.7k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cellmid Ltd
Glance View
Cellmid Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-12-09. The firm is specialized in developing anti-aging solutions. The firm operates through two segments: Diagnostics and Consumer Health. The firm is engaged in the research and development of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine. The company is also engaged in the development and sale of over the counter (OTC) and cosmetic products for hair loss and anti-aging hair care through its FGF5 inhibitor technology. The company has developed a range of products under the evolis, evolis Professional, Lexilis Hybrid, Jo-JuRED and Lexilis BLACK brands.
See Also
What is Cellmid Ltd's Income from Continuing Operations?
Income from Continuing Operations
-3.8m
AUD
Based on the financial report for Jun 30, 2021, Cellmid Ltd's Income from Continuing Operations amounts to -3.8m AUD.
What is Cellmid Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-5%
Over the last year, the Income from Continuing Operations growth was 13%. The average annual Income from Continuing Operations growth rates for Cellmid Ltd have been -1% over the past three years , -2% over the past five years , and -5% over the past ten years .
